ESTRO 2023 - Abstract Book

S1166

Digital Posters

ESTRO 2023

Conclusion CIRT did not affect the levels of CRP and TnI during and within 6 months after treatment for para and intra-cardiac tumours, while a significant change in NT-proBNP (increase and then reduction) was observed. After the initial increase, the reduction rate of NT-ProBNP was positively associated with some dosimetric parameters. Whether these biomarker changes increase the risk of long-term cardiovascular morbidity or mortality, will be addressed in the follow-up of our patients and with a larger prospective series.

PO-1440 miR-21 and miR-34a as biomarkers of radiotherapy skin adverse events in ductal carcinoma in situ

Abstract withdrawn.

PO-1441 Exploring the circulatory metabolic alterations in breast cancer patients

A. Jimenez Franco 1 , E. Rodríguez Tomàs 1 , C. Prats Lluis 2 , H. Castañe Vilafranca 3 , G. Baiges Gaya 4 , P. Araguas 5 , B. Malave 5 , D. Calderón 5 , J.C. Acosta 5 , M. Árquez 5 , R. Benavides 5 , F. Riu 6 , M. De la Flor 7 , C. Jordà 8 , M. Melé 9 , J. Repkova 9 , S. Sabater 5 , J. Camps 10 , J. Joven 10 , M. Arenas 5 1 Universitat Rovira i Virgili, Unitat de Recerca Biomèdica, Reus (Tarragona), Spain; 2 Universitat Rovira i Virgili, Radiation Oncology, Reus (Tarragona), Spain; 3 Institut d'Investigació Sanitària Pere Virgili, Unitat de Recerca Biomèdica, Reus (Tarragona), Spain; 4 Institut d'Investigació Sanitaria Pere Virgili, Unitat de Recerca Biomèdica, Reus (Tarragona), Spain; 5 Hospital Universitari Sant Joan de Reus, Radiation Oncology, Reus (Tarragona), Spain; 6 Hospital Universitari Sant Joan de Reus, Pathology, Reus (Tarragona), Spain; 7 Hospital Universitari Sant Joan XXIII, Gynecology, Tarragona, Spain; 8 Hospital Universitari Sant Joan de Reus, Gynecology, Reus (Tarragona), Spain; 9 Hospital Universitari Sant Joan de Reus, Medical Oncology, Reus (Tarragona), Spain; 10 Hospital Universitari Sant Joan de Reus, Unitat de Recerca Biomèdica, Reus (Tarragona), Spain Purpose or Objective Breast cancer (BC) is one of the most frequently diagnosed cancers and the main cause of cancer-related death among the women population. The interplay between metabolism, oxidative stress, and inflammatory processes appears to play an essential role in the development and progression of BC, according to growing research. In the present study, we aimed 1) to investigate the circulatory metabolic and immunity alterations, as well as the levels of proteins involved in oxidative stress in BC patients, and 2) to identify potential biomarkers associated with the pathophysiological characteristics of the patients. Materials and Methods 85 women with BC after their diagnoses, who had not yet received any oncological treatment, were recruited from two hospitals in Tarragona province (Spain). As a control group, we analysed samples from 50 healthy women without any carcinogenic evidence. We performed ELISA, colorimetric analyses, and semi-targeted metabolomics, to quantify circulatory metabolites involved in different metabolic pathways as well as the antioxidant enzyme paraoxonase-1 (PON1) and inflammatory indices (CCL2, IL-10 and TGF-beta). Results Using multivariate analysis, we identified several circulatory alterations in BC patients including the increased levels of glucose, VLDL-cholesterol, antiinflammatory cytokines (IL-10 and TGF-beta), and a decreased PON1 activity. Alterations in nucleotide and carbohydrate metabolism, such as 3-phosphoglyceric acid, xylonic acid and maltose, were seen in BC patients compared to healthy individuals. Post-menopausal state and triple negative (TN) molecular subtype were associated with alterations in inflammatory indices, an increase in tumour biomarkers (CEA and CA15.3) concentrations, and alterations in carbohydrate, lipids, amino acids, and nucleotides metabolism. Conclusion BC patients showed several alterations in the levels of proteins related with oxidative stress and immune response, as well as in metabolites involved in carbohydrates pathways. PON1 activity and hypoxanthine were the best parameters to discriminate between BC patients and controls.